WU-KONG28 is a multinational, open-label, randomized confirmatory phase 3 study evaluating ZEGFROVY versus platinum-based chemotherapy as first-line treatment in advanced NSCLC patients with EGFR exon20ins.
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for rst-line systemic treatment of plaque psoriasis with a targeted oral peptide ... rst-line-systemic-treatment-plaque-psoriasis.
Johnson & Johnson introduces the first and only IL-23R targeted ... https.//www.multivu.com/johnson-johnson/9378651-en-icotyde-icotrokinra-fda-approval-first-line-systemic-treatment-plaque-psoriasis.
- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -. - SELLAS’ Predictive Biomarker and AI Assisted PrecisionMedicineModels to be Utilized -. - Topline Data Expected in Q4 2026 – ... .
... for the first-line treatment of eligible adult patients with unresectable, locally advanced recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) whose tumours express PD-L1.
FOLFIRINOX and gemcitabine/nab-paclitaxel (gem/nab-p) are the most commonly used first-line regimens for advanced PDAC, yet limited actionable biomarker guidance exists for therapy selection.